With supplier issue now resolved, the Minnesota-run medtech company expects to “reach and then exceed” market growth in the ...

Atlanta-based Northside Hospital has treated its first patient using Medtronic's PulseSelect pulsed field ablation system for treating paroxysmal or persistent atrial fibrillation. The device, which ...

Medtronic — the world's largest medical device company — is preparing for potential new import taxes and other policy changes ...

CEO Geoff Martha said the business did not meet internal growth expectations last quarter due to third-party supply issues ...

Diabetes shines, cardiac ablation stumbles, and new products spark hope--Medtronic's Q2 FY25 shakes up expectations.

Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

From its cardiovascular divisions, Medtronic brought in $3.1 billion for an increase of 6.1%—driven in part by the launches ...

In this study, our results uncover the function and mechanism of CHMP5 in the regulation of cell senescence and bone formation in osteogenic cells. Deletion of Chmp5 causes endolysosomal dysfunction ...

When Tara Garcia was born, her skin was tinted blue. This meant a lack of oxygen in her body. Doctors told her parents the ...

Delivering on commitments, executing ahead of expectations, and raising guidanceInnovation driving sustained growth across many franchises: TAVR, PFA, Leadless Pacemakers, Diabetes, Spine ...

Boston Scientific announces favorable OPTION trial results for its WATCHMAN FLX LAAC device. In terms of stroke risk reduction, WATCHMAN FLX is found to be superior to OAC therapy.